Sangstat Medical Corporation

Other

The University of North Carolina at Chapel Hill

Ralph E Levy

Philippe J Pouletty

Moo J Cho

Laurence R Nicholson

Cliff Tyner

Robert A Britts

Debra L McEnroe

Disclosed are pharmaceutical compositions suitable for oral administration of bioactive peptides. Particularly, the pharmaceutical compositions comprise peptides formulated as suspensions stabilized with a dispersing agent. The compositions may be encapsulated in capsules for oral administration. The compositions show improved dissolution characteristics, which are believed to make them suitable for use in the treatment of gastrointestinal disorders.

Pharmaceutical compositions for bioactive peptide agents

Improved oral cyclosporin formulations which have high bioavailability and are capable of admiration in hard capsules are provided. In the subject formations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formalations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno-suppressive therapy.

Oral cyclosphorin formulations

A liquid medication dispenser apparatus which provides for user-friendly medication measurement and compliance. The apparatus measures and dispenses liquid medication doses and records the time and dose sizes for up to one year. The recorded information can then be downloaded to a personal computer for evaluation of patient compliance. A disposable, motor driven pump is used to provide a very wide range of medication dispensation volumes, while maintaining full accuracy and reducing the risks of patient errors as might occur with a manual dispense system.

Liquid medication dispenser apparatus

Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in both liquid and hard capsule form are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formulations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno-suppressive therapy.

Oral cyclosporin formulations

Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in hard capsules are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formulations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno-suppressive therapy.

Growing community of inventors

Pleasanton, CA, United States of America

Ralph E Levy